Pasithea Therapeutics Corp. (KTTA)Healthcare | Biotechnology | Miami Beach, United States | NasdaqCM
0.74 USD
+0.01
(0.870%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.73 -0.01 (-0.015%) ⇩ (April 17, 2026, 6:38 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:01 p.m. EDT
KTTA exhibits a volatile price pattern with recent dips and a current price near its 52-week low. The stock has a negative forward PE and trailing EPS, suggesting financial challenges. Despite insider buying and recent public offerings, the stock remains undervalued with a low price-to-book ratio, which may indicate potential for recovery. However, the lack of dividend history and the negative fundamentals suggest caution for long-term investors. Short-term traders might consider the recent dip as a potential buying opportunity, but the high risk and uncertain future performance make it a speculative play. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.150770 |
| AutoARIMA | 0.150774 |
| MSTL | 0.161901 |
| AutoTheta | 0.215376 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 71% |
| H-stat | 1.28 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.534 |
| Excess Kurtosis | -0.61 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 18,515,418 |
| Forward P/E | -0.35 |
| Beta | 0.25 |
| Website | https://www.pasithea.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.48531467 |
| Address1 | 1,111 Lincoln Road |
| Address2 | Suite 500 |
| All Time High | 170.0 |
| All Time Low | 0.281 |
| Ask | 0.7674 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 549,330 |
| Average Daily Volume3 Month | 331,296 |
| Average Volume | 331,296 |
| Average Volume10Days | 549,330 |
| Beta | 0.253 |
| Bid | 0.7348 |
| Bid Size | 2 |
| Book Value | 2.391 |
| City | Miami Beach |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.7424 |
| Current Ratio | 11.351 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.7588 |
| Day Low | 0.7317 |
| Display Name | Pasithea Therapeutics |
| Earnings Timestamp End | 1,755,374,400 |
| Earnings Timestamp Start | 1,754,942,400 |
| Ebitda | -16,031,099 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 2.286 |
| Enterprise Value | -36,643,520 |
| Eps Current Year | -1.86 |
| Eps Forward | -2.1 |
| Eps Trailing Twelve Months | -2.91 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.78066 |
| Fifty Day Average Change | -0.038259983 |
| Fifty Day Average Change Percent | -0.049009793 |
| Fifty Two Week Change Percent | -48.531467 |
| Fifty Two Week High | 3.79 |
| Fifty Two Week High Change | -3.0476 |
| Fifty Two Week High Change Percent | -0.80411613 |
| Fifty Two Week Low | 0.281 |
| Fifty Two Week Low Change | 0.4614 |
| Fifty Two Week Low Change Percent | 1.6419929 |
| Fifty Two Week Range | 0.281 - 3.79 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,631,712,600,000 |
| Float Shares | 14,262,408 |
| Forward Eps | -2.1 |
| Forward P E | -0.35352382 |
| Free Cashflow | -6,473,837 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0149300005 |
| Held Percent Institutions | 0.69911003 |
| Implied Shares Outstanding | 24,939,948 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-09-15 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,704,153,600 |
| Last Split Factor | 1:20 |
| Long Business Summary | Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. |
| Long Name | Pasithea Therapeutics Corp. |
| Market | us_market |
| Market Cap | 18,515,418 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_702706441 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -20,427,684 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 18,702,467 |
| Number Of Analyst Opinions | 1 |
| Open | 0.7317 |
| Operating Cashflow | -15,211,490 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 786 977 3380 |
| Post Market Change | -0.014800012 |
| Post Market Change Percent | -1.9935361 |
| Post Market Price | 0.7276 |
| Post Market Time | 1,776,465,484 |
| Previous Close | 0.736 |
| Price Eps Current Year | -0.39913976 |
| Price Hint | 4 |
| Price To Book | 0.3104977 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.09 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00639999 |
| Regular Market Change Percent | 0.869564 |
| Regular Market Day High | 0.7588 |
| Regular Market Day Low | 0.7317 |
| Regular Market Day Range | 0.7317 - 0.7588 |
| Regular Market Open | 0.7317 |
| Regular Market Previous Close | 0.736 |
| Regular Market Price | 0.7424 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 213,397 |
| Return On Assets | -0.27347 |
| Return On Equity | -0.58362997 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 24,939,948 |
| Shares Percent Shares Out | 0.0049 |
| Shares Short | 122,487 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 173,570 |
| Short Name | Pasithea Therapeutics Corp. |
| Short Percent Of Float | 0.005 |
| Short Ratio | 1.18 |
| Source Interval | 15 |
| State | FL |
| Symbol | KTTA |
| Target High Price | 3.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 3.0 |
| Target Median Price | 3.0 |
| Total Cash | 55,158,940 |
| Total Cash Per Share | 2.212 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.91 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.81172 |
| Two Hundred Day Average Change | -0.06932002 |
| Two Hundred Day Average Change Percent | -0.085398935 |
| Type Disp | Equity |
| Volume | 213,397 |
| Website | https://www.pasithea.com |
| Zip | 33,139 |